Mabion Toekomstige groei
Future criteriumcontroles 0/6
Mabion's revenue and earnings are forecast to decline at 10.4% and 116.7% per annum respectively.
Belangrijke informatie
-116.7%
Groei van de winst
n/a
Groei van de winst per aandeel
| Biotechs winstgroei | 36.4% |
| Inkomstengroei | -10.4% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 29 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 24
Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For Growth
Nov 28Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue Forecasts
Jun 02Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?
Jul 09Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good News
Jun 04Is Mabion (WSE:MAB) Using Too Much Debt?
Dec 22Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value Estimate
Sep 11How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?
Feb 24Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 90 | -18 | -17 | 11 | 2 |
| 12/31/2025 | 92 | -10 | -29 | 1 | 3 |
| 12/31/2024 | 99 | 12 | 8 | 27 | 2 |
| 9/30/2024 | 111 | 10 | 15 | 47 | N/A |
| 6/30/2024 | 140 | 37 | 12 | 55 | N/A |
| 3/31/2024 | 146 | 42 | -41 | 4 | N/A |
| 12/31/2023 | 152 | 41 | -40 | -2 | N/A |
| 9/30/2023 | 148 | 58 | 34 | 62 | N/A |
| 6/30/2023 | 157 | 42 | 33 | 52 | N/A |
| 3/31/2023 | 165 | 32 | 69 | 84 | N/A |
| 12/31/2022 | 164 | 23 | 22 | 39 | N/A |
| 9/30/2022 | 156 | 45 | -67 | -46 | N/A |
| 6/30/2022 | 117 | 34 | -52 | -24 | N/A |
| 3/31/2022 | 75 | 26 | -109 | -75 | N/A |
| 12/31/2021 | 36 | 2 | -65 | -33 | N/A |
| 9/30/2021 | 2 | -51 | -38 | -20 | N/A |
| 6/30/2021 | 2 | -45 | -58 | -49 | N/A |
| 3/31/2021 | N/A | -53 | -13 | -10 | N/A |
| 12/31/2020 | N/A | -56 | -39 | -35 | N/A |
| 9/30/2020 | N/A | -55 | -40 | -35 | N/A |
| 6/30/2020 | N/A | -63 | -35 | -30 | N/A |
| 3/31/2020 | N/A | -69 | -37 | -31 | N/A |
| 12/31/2019 | N/A | -64 | -43 | -34 | N/A |
| 9/30/2019 | N/A | -65 | -42 | -31 | N/A |
| 6/30/2019 | N/A | -59 | -36 | -24 | N/A |
| 3/31/2019 | N/A | -70 | -44 | -34 | N/A |
| 12/31/2018 | N/A | -69 | -46 | -39 | N/A |
| 9/30/2018 | N/A | -72 | -48 | -42 | N/A |
| 6/30/2018 | N/A | -74 | N/A | -62 | N/A |
| 3/31/2018 | N/A | -59 | N/A | -61 | N/A |
| 12/31/2017 | N/A | -58 | N/A | -54 | N/A |
| 9/30/2017 | N/A | -56 | N/A | -35 | N/A |
| 6/30/2017 | N/A | -57 | N/A | -24 | N/A |
| 3/31/2017 | N/A | -59 | N/A | -26 | N/A |
| 12/31/2016 | N/A | -56 | N/A | -15 | N/A |
| 9/30/2016 | 0 | -77 | N/A | -36 | N/A |
| 6/30/2016 | 0 | -65 | N/A | -44 | N/A |
| 3/31/2016 | 3 | -51 | N/A | -30 | N/A |
| 12/31/2015 | 3 | -43 | N/A | -32 | N/A |
| 9/30/2015 | 3 | -6 | N/A | -29 | N/A |
| 6/30/2015 | 3 | -5 | N/A | -24 | N/A |
| 3/31/2015 | 1 | -5 | N/A | -30 | N/A |
| 12/31/2014 | 1 | -4 | N/A | -24 | N/A |
| 9/30/2014 | 1 | -4 | N/A | -20 | N/A |
| 6/30/2014 | 0 | -4 | N/A | -26 | N/A |
| 3/31/2014 | 0 | -4 | N/A | -23 | N/A |
| 12/31/2013 | 0 | -4 | N/A | -28 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: MAB's earnings are forecast to decline over the next 3 years (-116.7% per year).
Winst versus markt: MAB's earnings are forecast to decline over the next 3 years (-116.7% per year).
Hoge groeiwinsten: MAB's earnings are forecast to decline over the next 3 years.
Omzet versus markt: MAB's revenue is expected to decline over the next 3 years (-10.4% per year).
Hoge groei-inkomsten: MAB's revenue is forecast to decline over the next 3 years (-10.4% per year).
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if MAB's Return on Equity is forecast to be high in 3 years time